First-in-human Phase 1 Study of CC-94676, a First-in-class Androgen Receptor (AR) Ligand-Directed Degrader (LDD), in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

Dana E. Rathkopf,Manish R. Patel,Atish Dipankar Choudhury,Drew W. Rasco,Nehal J. Lakhani,Jessica E. Hawley,Ana Aparicio,Vivek Narayan,Sandy Srinivas,Karie Runcie,Hamid Emamekhoo,Zachery R. Reichert,Michael Anthony Carducci, Amber L. Wells,Can Liu,Raju Kandimalla, Jiaju Wu, Marie Huong Nguyen,Michael Pourdehnad,Andrew J. Armstrong

JOURNAL OF CLINICAL ONCOLOGY（2024）

Cited 0|Views8

No score

Key words

283-2494-5577-2829-12292,261-566-148,261-137-7318-7319,283-2494-5577-2829-12292,3282-206-4957-3975-3408-6824,613-545-552,261-492-199-2823-10594-7548-5180,261-436,60,162,256,2946,143,1917,38092-18135,38092-18135

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined